Absci Q2 net loss $30.6M; raises $64M in July extending runway to H1 2028; Almirall collaboration expands

Absci Corp

2025-Q2 EPS reported -$0.45 revenue$1,772,000

Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).
Raised $64M ($50M public offering + $14M ATM) in July 2025; cash+investments $117.5M at June 30; runway into H1 2028.
Expanded Almirall collaboration: second target elected for dermatology; up to $650M in potential milestones across two programs.
ABS-101 Phase 1 interim data expected H2 2025; ABS-201 on track for Phase 1/2a start early 2026 with efficacy readout H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.